Shivchem Agro IPO: Real Profit and Spare Capacity, but Cash Is Still Tied Up in Stock and Credit

1. IPO Overview

Shivchem Agro Limited is raising money through a 100% fresh issue on the SME platform of BSE Limited.

2. What the company does

Shivchem Agro makes crop-protection chemicals and fertilisers that help farmers protect crops and grow more from the same field.

What it makes

The company does not invent new chemicals. It buys the active killing ingredient plus solvents, fillers and packing, then mixes and packs them into bottles, pouches and bags that farmers can spray or scatter.

Its licence book is wide for a young company incorporated in 2021. It holds licences for 176 agrochemical products under the Insecticides Act, 1968 and authorisation for 82 fertilisers under the Fertilizer Control Order, 1985. In practice it sells six lines.

• Insecticides kill bugs such as stem borers, bollworms, aphids and termites.
• Herbicides kill weeds that steal water and nutrients from crops.
• Fungicides fight fungi that rot rice, potato, fruit, vegetables and grapes.
• Plant growth regulators are hormones that alter growth, flowering or rooting.
• Rodenticides control rats and mice in fields and godowns.
• Fertilisers feed the soil with nitrogen, phosphorus, potassium and micronutrients.

Herbicides are now the largest line, followed by insecticides and fungicides. Fertilisers are licensed widely but sold narrowly so far, which makes the licence book an option on future sales rather than current revenue.

The mix has shifted sharply over three full years ended March 31. All amounts below are as printed in Rs. crore.

Insecticides fell in absolute sales in the latest year while herbicides roughly doubled and fungicides more than tripled. That spread reduces dependence on one product, though it also shows how quickly the mix can swing with seasons and demand.

How it makes them

Everything is formulated at one factory at Barhana, village Jhajjar, Haryana. Raw materials are checked, weighed, pre-mixed, milled to shrink particle size, then granulated or suspended or emulsified, dried where needed, blended with dyes and stabilisers, sieved, tested and packed.

The plant can make solids and liquids, including granules, water-dispersible granules, suspension concentrates and emulsifiable concentrates. The document says filling, packaging and labelling use fully automatic machines, which should cut manual error.

Installed capacity has been flat at 65,07,500 kg/litre for the last two years, after rodenticides and fertilisers were added in FY 2024-25. Use remains low except in two lines, so extra demand can be met without building a new plant for now.

Who buys and how they pay

Shivchem does not sell directly to farmers. It sells to independent distributors, plus a smaller set of non-distributors, who sell on to retailers and farmers.

As at March 31, 2026 it had 685 distributors served through five rented godowns in Andhra Pradesh, Telangana, Odisha, Assam and Bihar, plus the factory store in Haryana. A 39-person sales and marketing team works with distributors, runs training and field demonstrations, and posts product videos and blogs to teach dosage and use.

The commercial rule is simple and tough on cash. Operations are on purchase orders, with no long-term customer contracts disclosed. In line with industry practice, distributors generally pay only after they have sold the entire lot they bought. That is why money owed by customers is large and slow.

Discounts and rebates are used to keep distributors motivated. Concentration at the top is moderate but not trivial, with the top 10 customers taking about 29% of sales in the latest year. Growth has come mainly from hunting new customers rather than repeat orders, which keeps the funnel wide but makes collection and forecasting harder.

Geography shows the same widening story. All amounts in Rs. crore as printed.

Andhra Pradesh remains the largest market but its share fell as Telangana, Odisha and Bihar were added or scaled. The company is licensed to sell in eight states, though no revenue is shown from Uttar Pradesh and Madhya Pradesh in these three years.

How big it is

The operating footprint has been built quickly. Distributors rose from 185 to 516 to 685 in three years, while staff rose from 40 to 66 and the sales team from 17 to 39. Licensed products rose from 232 to 258 and then held flat.

What decides growth from here is whether more distributors order again, whether herbicides and fungicides keep filling the plant, and whether new licences and states turn into repeat sales rather than one-time stocking.

3. Use of Funds

The entire issue is fresh shares, so all net proceeds go to the company. Money from an offer for sale, which is shares sold by existing owners, does not apply here because there is no offer for sale.

The stated uses are:

• Rs 6.90 crore for working capital needs in FY 2026-27, mainly to fund stock and credit to distributors.
• Rs 3.50 crore for repayment or prepayment of certain loans, in full or part.
• Balance for general corporate purposes, where the amount is not disclosed as a figure.

The working-capital and loan-repayment objects together total Rs 10.40 crore. The document says the working-capital need for FY 2026-27 is much larger than Rs 6.90 crore and will also be met from internal accruals and other means.

4. Financials Overview

All figures below are restated standalone for full 12-month years ended March 31, since the company discloses no subsidiary and presents no consolidated statements.

Revenue roughly tripled over two years, while operating profit also roughly tripled and net profit more than doubled. Margins dipped in the middle year and then recovered, and leverage fell sharply as equity was injected. Operating cash was negative in the first two years and turned positive only in the latest year, at a level well below profit. The deep dive follows in the next section.

5. What the financials tell us

The financial picture is straightforward. Shivchem makes real operating profit from mixing and selling chemicals, and it has plenty of factory room to grow. But growth soaks up cash in raw materials and credit to distributors, so it leans on long supplier credit and costly borrowing while part of its cash sits outside operations in a promoter property advance.

Sales grew slower but spread across more products

Sales kept growing in FY 2025-26 but at a far slower pace than before, which is natural as the base got bigger. The document links the rise to more sales in certain product groups plus a wider distributor web and deeper market reach.

The important change is the mix. Insecticides, once well over half of sales, fell sharply in the latest year to under a third. Herbicides took the lead at over two-fifths after roughly doubling, while fungicides and plant growth regulators grew strongly from small bases.

That broadening matters for an investor for two reasons:

• Less reliance on one line means a pest season or price fall in insecticides hurts less than before.
• Faster growth in herbicides and fungicides filled the busiest plant lines, which helps spread fixed costs.

Much of the factory is still empty

Total capacity did not change in the latest year and only about 23% of it was used. The busiest lines were herbicides at about 57% and fungicides at about 43%, while insecticides ran at about 26% and other lines ran in single digits.

The document says early low use reflected building visibility and demand, and that it makes only what the market needs now. Rodenticides and fertilisers were added only in FY 2024-25, so their low use is less surprising.

For an investor this means near-term growth does not need a new building. Extra herbicide and fungicide volumes can come from the existing Jhajjar plant if demand arrives. The risk is the mirror image: if demand stalls, fixed costs sit on thin volumes and low-use lines stay idle.

Cash gets stuck in stock and customer credit

This is the central strain. Raw-material stock and money owed by customers both grew faster than sales, while supplier balances also grew very large and funded part of the gap.

The business reasons are disclosed. The company buys some materials ahead for peak demand, holds finished goods in five godowns far from Haryana, and lets distributors pay only after they resell the lot. Receivable days stretched from 87 to 102 to 151 days, raw-material days jumped to 259 days, and payable days stretched past 300 days.

The cash result shows the pressure:

• Operating cash was deeply negative for two years as stock and receivables were built.
• It turned positive in FY 2025-26 but at only about half of profit, so profit and cash still diverge.

The Rs 6.90 crore of IPO money for working capital will help fund a much larger projected need next year, alongside internal accruals. But unless stock days and collection days actually fall, cash will stay tied up and growth will keep needing outside funding. Whether suppliers will keep waiting over 300 days is also not assured.

Profit comes from operations, but interest eats a large share

Almost all profit comes from making and selling chemicals. Other income was only about Rs 2 lakhs against profit of about Rs 3.25 crore, with no exceptional items, so there is no clean-up needed to understand earnings. With no subsidiaries, total profit is the owners profit.

The drag is finance cost. Interest rose sharply as borrowings were used to fund expansion, reaching about two-fifths of last-year profit on total borrowings of about Rs 7.28 crore. Debt to equity looks far better than two years ago, but that is mainly because equity was injected from a tiny base, not because debt vanished.

The plan to use Rs 3.50 crore to repay part of about Rs 5.71 crore outstanding, including very high-rate unsecured loans at rates such as 34% and 18.5% alongside bank loans, should lower interest if the costliest loans are picked. The document does not say which loans will be repaid or the saving after any prepayment charges, so the margin benefit cannot be quantified here.

Promoter property money still sits outside the business

At March 31, 2026 the company had paid capital advances of about Rs 2.38 crore to two promoters for two properties. The Rs 1.02 crore advance to one promoter was repaid after year-end, leaving about Rs 1.36 crore to the other promoter still outstanding while that purchase completes.

If the company itself fails to complete that purchase, the seller can keep up to about Rs 17 lakhs, or about 5% of last-year profit. Director unsecured loans are now tiny, so the issue is not ongoing promoter borrowing but cash locked in a non-operating advance.

For a business that needs cash for stock and distributor credit, that lock-up matters. It is about a tenth of net worth sitting outside operations until the deal completes, with a small loss risk if the deal fails.

6. Valuation Analysis

The right lens here is earnings, because Shivchem is a profitable operating company with no subsidiaries and no complex structure. Book value matters as a cross-check for a small manufacturer, but the call will turn on whether reported profit converts to cash and survives interest and working-capital costs.

At the top of the band, Rs 62 a share, the company is valued at Rs 46.70 crore after the issue, on 75,32,873 post-issue shares. That is 14.4 times reported profit of Rs 3.25 crore for the year ended March 31, 2026. At the floor, Rs 59 a share, the value is Rs 44.44 crore, or 13.7 times the same profit. On the prospectus pre-issue earnings base of Rs 6.16 a share on 52,72,873 weighted shares, the band is 9.6 times at Rs 59 and 10.1 times at Rs 62.

Against the two listed peers, the band is at a clear discount on earnings. The peer median is 21.52 times, with a range of 15.21 times to 27.83 times, so Shivchem at 13.7 to 14.4 times post-issue is about a third below the median and about 5% to 10% below the cheapest peer. Pre-issue, the discount is even wider.

Part of that discount looks earned rather than a bargain. Shivchem grew far faster and earns higher margins and returns on capital than both peers, which would normally command a premium. But its operating cash was only about half of profit, receivables and stocks are stretched, supplier funding runs past 300 days, liquidity is thinner, scale is smaller and about Rs 1.36 crore remains locked in a promoter advance. In other words, the same rupee of profit is riskier because it is not yet cash. The price is fair only if IPO working capital and loan repayment genuinely shorten stock, collection and payable days without losing distributors.

7. Peer Analysis

Basis: standalone FY 2025-26; subject post-issue P/E on reported PAT on 75,32,873 shares at Rs 59 to Rs 62, peers at August 31, 2026 closing prices on BSE and NSE as per the offer document.

Source: RHP — Comparison of financial KPIs of our Company and our Listed Peers; pages 138-140. Basis: Standalone. Calculated from the RHP's revenue figures; every other cell is as printed.

Shivchem really compares with Super Crop Safe, the closer-sized formulator, and Sikko Industries, the larger but slower-growing peer. Both are in the same formulation business in India, though the document warns they are not strictly comparable and discloses no peer capacity, distributor or product data.

Three differences matter. First, Shivchem grew far faster off a tiny base by adding distributors and hunting new customers, while peers grew on larger bases at far slower rates. Second, Shivchem holds margins near high teens and returns on capital near 30%, while Super Crop margins compressed and Sikko sits in high single digits. Third, Shivchem converts less profit to cash and funds the gap with suppliers, with receivables, stocks and payables all stretched further than Super Crop current position.

Cash strain is partly shared, since both peers also had negative operating cash years, but the extreme supplier funding, 151-day receivables with cheque-dishonour cases, and promoter advance are specific to Shivchem. The discount to peers is therefore partly earned for liquidity and governance risk, not for operating performance. Where peer figures come from the peers own exchange filings rather than the offer document calculations, that is noted in the source lines above.

8. Moat

What makes it different

Shivchem has no patent or proprietary chemistry disclosed. Its edge is execution breadth on a small base: 258 licensed products, 685 distributors, a 39-person sales team, and a plant that can make both solids and liquids with automated filling.

That combination is real but not hard in the technical sense. Any rival can in time seek licences, hire salespeople and buy filling machines. What is harder to copy quickly is the field network and trust built through demonstrations, repeat distributor relationships and a content library of dosage videos. The document shows distributor KPIs that peers do not disclose, which suggests a sales-led culture, but ISO certificates and videos alone are table stakes rather than a lasting moat.

Durability therefore rests on keeping licences live and distributors reordering, not on a protected product. If service slips or a rival offers better discounts or exclusive terms, distributors can switch because there are no long-term contracts.

Tailwinds

Outside forces help if the company can collect cash to serve them.

• Global agrochemical demand is forecast by the industry report to grow at about 4.7% a year to USD 273.5 billion by 2029, which widens the market for insecticides, herbicides and fungicides.
• The domestic market, where all Shivchem sales are earned, is projected to grow faster at about 11.8% a year to USD 39.4 billion, which directly lifts the addressable pie.
• Government focus on farm output and food security, through schemes and policy support, supports volumes for crop-protection and nutrition products.
• A Make in India push for self-reliance favours domestic formulators against Chinese generic pressure, though price competition remains intense.

These tailwinds reach Shivchem only through distributors and farmer re-purchase. A good monsoon and pest pressure help volumes, while drought, floods or a shift to bio-pesticides can hurt chemical volumes for the whole industry.

How durable the edge is

There is no hard moat here, only advantages that rivals can match. Licence breadth and distributor reach can wear down if compliance lapses, if key suppliers fail, or if working-capital stress forces tighter credit that small distributors cannot accept. The plant has headroom, but headroom without repeat demand is just idle capacity. The edge lasts only as long as the company keeps adding useful licences, keeps distributors profitable, and turns sales into cash faster than before.

9. Risks

• Input costs and single-supplier dependence. Materials are over three-fifths of total expenses and the top supplier is about a third of purchases, with the top 10 over 70%. There are no long-term supply contracts disclosed. If prices spike or a key supplier fails, margins compress or deliveries slip because costs cannot always be passed to price-sensitive distributors.

• Distributor credit and cash collection. Distributors pay after they resell, so receivables are half of sales and now sit at 151 days. The company has already filed cheque-dishonour cases for small amounts. Longer credit may keep small distributors, but it forces borrowings and discounts and has produced two years of negative operating cash before a weak positive year. This risk is partly industry-wide but the stretch here is company-specific.

• Recallable and costly debt. Total borrowings are about Rs 7.28 crore, including unsecured loans that lenders can recall at any time, with some rates as high as 34% and 18.5%. Promoter personal guarantees and covenants that need lender consent for capital changes add fragility. The Rs 3.50 crore repayment helps only if it targets the costliest recallable loans.

• Promoter advances and governance. About Rs 1.36 crore remains with a promoter for a property purchase, with up to about Rs 17 lakhs forfeitable if the company defaults. Past delays in statutory dues, gaps in Registrar filings including an INC-20A delay that drew penalties, and a promoter-linked bank dispute over asset classification add governance noise. These are idiosyncratic, not industry risks, and they have not improved fully over the period.

• Licences, leases and competition. Manufacturing and sale hinge on Insecticides Act and fertiliser permissions, pollution consents and state sale licences. The factory, office and godowns are all leased, including the factory from a promoter. The market is crowded and often price-led, with 22 trademarks applied but 19 objected, so brand protection is weak. Loss of a licence, lease or key distributor set would hit sales quickly.

10. Verdict

Shivchem is a real, profitable formulator with a broad licence book, a fast-built distributor web and spare plant to grow into, but its profit is still not cash because stock and distributor credit tie up funds while suppliers and high-rate loans bridge the gap.

That leaves three load-bearing facts already laid out: operating profit is genuine and broadened beyond insecticides, operating cash is only about half of profit after two negative years with stocks and receivables stretched, and the balance sheet still carries costly recallable debt plus a promoter property advance outside operations. The band prices earnings at a discount to peers, which is justified for cash and governance risk rather than operating weakness.

The thesis works only if IPO working capital plus loan repayment genuinely cut collection and stock days toward management target of nearer 100 days without losing distributors, so that cash converges toward profit and interest falls. It breaks if receivables and stocks stay stretched, supplier credit snaps back, or growth keeps needing discounts and borrowings, in which case the earnings discount proves to be working-capital risk priced in.